Seth Klarman · Q1 2018
Baupost Group
Portfolio at the end of Q1 2018, from the 13F filed May 14, 2018. See the filing on EDGAR ↗
| Company | Weight | Held since | Change |
|---|---|---|---|
| Cheniere Energy LNG · history | 10.7% | Q1 2014 | No change |
| Synchrony SYF · history | 9.5% | Q3 2016 | No change |
| Twenty-First Century Fox FOXA · history | 9.4% | Q3 2015 | Add 19% |
| Viasat VSAT · history | 8.7% | Q2 2013 or earlier | Add 4% |
| Allergan AGN · history | 7.7% | Q1 2016 | Add 6% |
| Qorvo QRVO · history | 7.5% | Q1 2017 | No change |
| Time Warner TWX · history | 7.4% | Q4 2017 | No change |
| Pioneer Natural Resources PXD · history | 6.6% | Q3 2017 | Add 100% |
| Antero Resources AR · history | 5.1% | Q3 2014 | Add 8% |
| Twenty-First Century Fox FOX · history | 4.0% | Q3 2015 | Add 9% |
| Cardinal Health CAH · history | 3.1% | Q4 2016 | No change |
| Colony NorthStar CLNS · history | 2.7% | Q1 2017 | Add 4% |
| PBF Energy PBF · history | 2.6% | Q3 2013 | Reduce 27% |
| Atara Biotherapeutics ATRA · history | 2.4% | Q4 2014 | Add 17% |
| McKesson MCK · history | 2.2% | Q3 2017 | Add 19% |
| Theravance Biopharma TBPH · history | 2.2% | Q2 2014 | No change |
| Veritiv VRTV · history | 1.4% | Q3 2014 | Add 5% |
| PG&E PCG · history | 1.3% | Q1 2018 | Buy |
| Cencora COR · history | 1.1% | Q3 2017 | Reduce 8% |
| Keryx Biopharmaceuticals KERX · history | 1.0% | Q1 2014 | No change |
| AMC Entertainment AMC · history | 0.7% | Q3 2017 | No change |
| Novagold Resources NG · history | 0.6% | Q2 2013 or earlier | Add 25% |
| Tesla TSLA.CV · convertible notes · history | 0.5% | Q1 2018 | Buy |
| GTY Technology GTYH.U · units · history | 0.4% | Q4 2016 | No change |
| Paratek Pharmaceuticals PRTK · history | 0.3% | Q4 2014 | No change |
| Theravance Biopharma TBPH.CV · convertible notes · history | 0.3% | Q4 2016 | No change |
| Saban Capital Acquisition SCAC · history | 0.2% | Q4 2016 | No change |
| Sentinel Energy Services STNL.U · units · history | 0.2% | Q4 2017 | No change |
| ChipMOS IMOS · history | 0.1% | Q2 2013 or earlier | Reduce 37% |
| Trilogy Metals TMQ · history | 0.1% | Q2 2013 or earlier | No change |
| Forward Pharma FWP · history | 0.1% | Q4 2014 | Reduce 32% |
| Saban Capital Acquisition SCAC.WS · warrants · history | 0.0% | Q4 2016 | No change |
| Orexigen Therapeutics OREX · history | 0.0% | Q3 2015 | No change |
| 33 positions | 100.0% |
Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q4 2017, adjusted for stock splits.
Sector weighting
| Media & telecom | 30.1% | |
|---|---|---|
| Energy | 25.0% | |
| Health care | 20.3% | |
| Financials & real estate | 12.6% | |
| Technology | 8.1% | |
| Industrials | 1.4% | |
| Utilities | 1.3% | |
| Materials | 0.7% | |
| Consumer discretionary | 0.5% |
What changed from Q4 2017
- Buy PG&E PCG 1.3% of the 13F
- Buy Tesla TSLA.CV 0.5% of the 13F
- Add 19% Twenty-First Century Fox FOXA 7.6% → 9.4%
- Add 4% Viasat VSAT 9.7% → 8.7%
- Add 6% Allergan AGN 7.3% → 7.7%
- Add 100% Pioneer Natural Resources PXD 3.4% → 6.6%
- Add 8% Antero Resources AR 4.6% → 5.1%
- Add 9% Twenty-First Century Fox FOX 3.6% → 4.0%
- Add 4% Colony NorthStar CLNS 5.4% → 2.7%
- Add 17% Atara Biotherapeutics ATRA 1.0% → 2.4%
- Add 19% McKesson MCK 2.1% → 2.2%
- Add 5% Veritiv VRTV 1.0% → 1.4%
- Add 25% Novagold Resources NG 0.4% → 0.6%
- Reduce 27% PBF Energy PBF 3.8% → 2.6%
- Reduce 8% Cencora COR 1.3% → 1.1%
- Reduce 37% ChipMOS IMOS 0.3% → 0.1%
- Reduce 32% Forward Pharma FWP 0.2% → 0.1%
- Sell Express Scripts ESRX was 1.7%
- Sell Cascadian Therapeutics CASC was 0.3%
- Sell Sunrun RUN was 0.2%